Compare TW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TW | INSM |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 23.0B |
| IPO Year | 2019 | 2000 |
| Metric | TW | INSM |
|---|---|---|
| Price | $99.18 | $102.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $135.25 | ★ $201.17 |
| AVG Volume (30 Days) | 1.8M | ★ 4.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $892,659,000.00 | N/A |
| Revenue This Year | $18.07 | $182.31 |
| Revenue Next Year | $10.66 | $65.19 |
| P/E Ratio | $102.29 | ★ N/A |
| Revenue Growth | ★ 15.10 | N/A |
| 52 Week Low | $94.25 | $90.39 |
| 52 Week High | $147.49 | $212.75 |
| Indicator | TW | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 45.73 |
| Support Level | $95.65 | $98.90 |
| Resistance Level | $112.41 | $166.81 |
| Average True Range (ATR) | 2.71 | 5.41 |
| MACD | 0.35 | 1.39 |
| Stochastic Oscillator | 28.05 | 72.79 |
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.